Today, a Director at Celgene (NASDAQ: CELG), Ernest Mario, sold shares of CELG for $1.11M.
In addition to Ernest Mario, one other CELG executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Celgene’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $3.83 billion and quarterly net profit of $1.05 billion. In comparison, last year the company earned revenue of $3.19 billion and had a net profit of $1.06 billion. CELG’s market cap is $64.08B and the company has a P/E ratio of 25.06. Currently, Celgene has an average volume of 3.62M.
Based on 15 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $119.09, reflecting a -23.6% downside. Three different firms, including Goldman Sachs and Morgan Stanley, currently also have a Sell rating on the stock.
In the last 30 days, insiders have sold $1.11M worth of CELG shares and purchased $500.2K worth of CELG shares. The insider sentiment on Celgene has been positive according to 48 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company’s products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. Celgene was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.
Read More on CELG:
